Veradermics

Veradermics (Ticker: MANE US) develops treatments for aesthetic and dermatological conditions, including an oral extended-release minoxidil product being developed for pattern hair loss in men and women. Its lead product, VDPHL01, is an oral extended-release formulation of minoxidil for pattern hair loss in men and women. Planned use of IPO proceeds includes funding pivotal Phase 2 and Phase 3 clinical trials for VDPHL01 and preparing for a New Drug Application submission. Wellington Management indicated interest in purchasing up to $30.00 million of the offered shares.

The scheduled listing date on NYSE was February 4, 2026. The proposed offering comprises 13,350,000 shares at an indicative price range of $14.00–16.00 per share. At the indicative range midpoint, the base offering would represent $200.25 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $500.00 million.

Jefferies, Leerink Partners, and Citigroup are the underwriters leading the offering.